Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 91.5b

Swedish Orphan Biovitrum Valuation

Is SOBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 985.56
Fair Value
73.0% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: SOBI (SEK266.4) is trading below our estimate of fair value (SEK985.56)

Significantly Below Fair Value: SOBI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOBI?

Key metric: As SOBI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOBI. This is calculated by dividing SOBI's market cap by their current earnings.
What is SOBI's PE Ratio?
PE Ratio23.6x
EarningsSEK 3.89b
Market CapSEK 91.49b

Price to Earnings Ratio vs Peers

How does SOBI's PE Ratio compare to its peers?

The above table shows the PE ratio for SOBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.3x
VITR Vitrolife
41.2x16.6%SEK 21.1b
BIOG B BioGaia
29.2x15.0%SEK 10.3b
BONEX Bonesupport Holding
157x47.8%SEK 21.0b
CAMX Camurus
78x52.4%SEK 33.4b
SOBI Swedish Orphan Biovitrum
23.6x16.6%SEK 91.5b

Price-To-Earnings vs Peers: SOBI is good value based on its Price-To-Earnings Ratio (23.6x) compared to the peer average (76.3x).

Price to Earnings Ratio vs Industry

How does SOBI's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SOBI 23.6xIndustry Avg. 22.1xNo. of Companies6PE01632486480+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SOBI is expensive based on its Price-To-Earnings Ratio (23.6x) compared to the European Biotechs industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is SOBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOBI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.6x
Fair PE Ratio49.1x

Price-To-Earnings vs Fair Ratio: SOBI is good value based on its Price-To-Earnings Ratio (23.6x) compared to the estimated Fair Price-To-Earnings Ratio (49.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOBI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 266.40
SEK 361.50
+35.7%
9.4%SEK 400.00SEK 285.00n/a12
Apr ’26SEK 285.60
SEK 366.33
+28.3%
9.2%SEK 400.00SEK 285.00n/a12
Mar ’26SEK 315.60
SEK 368.42
+16.7%
9.5%SEK 405.00SEK 285.00n/a12
Feb ’26SEK 335.80
SEK 366.08
+9.0%
10.7%SEK 415.00SEK 275.00n/a12
Jan ’26SEK 317.40
SEK 359.73
+13.3%
10.6%SEK 400.00SEK 275.00n/a11
Dec ’25SEK 302.40
SEK 360.64
+19.3%
10.9%SEK 410.00SEK 275.00n/a11
Nov ’25SEK 329.40
SEK 351.27
+6.6%
11.2%SEK 410.00SEK 275.00n/a11
Oct ’25SEK 309.00
SEK 325.55
+5.4%
8.9%SEK 370.00SEK 250.00n/a11
Sep ’25SEK 320.00
SEK 328.00
+2.5%
8.5%SEK 370.00SEK 250.00n/a11
Aug ’25SEK 278.00
SEK 328.30
+18.1%
8.9%SEK 370.00SEK 250.00n/a10
Jul ’25SEK 285.80
SEK 329.60
+15.3%
6.2%SEK 370.00SEK 285.00n/a10
Jun ’25SEK 282.40
SEK 320.00
+13.3%
9.4%SEK 370.00SEK 252.00n/a10
May ’25SEK 285.40
SEK 317.22
+11.2%
9.8%SEK 370.00SEK 252.00n/a9
Apr ’25SEK 267.20
SEK 317.70
+18.9%
9.6%SEK 370.00SEK 252.00SEK 285.6010
Mar ’25SEK 260.80
SEK 317.91
+21.9%
9.2%SEK 370.00SEK 252.00SEK 315.6011
Feb ’25SEK 278.00
SEK 316.20
+13.7%
8.0%SEK 345.00SEK 252.00SEK 335.8010
Jan ’25SEK 267.00
SEK 297.00
+11.2%
6.0%SEK 325.00SEK 252.00SEK 317.4010
Dec ’24SEK 250.60
SEK 293.00
+16.9%
7.0%SEK 325.00SEK 252.00SEK 302.4010
Nov ’24SEK 234.00
SEK 287.45
+22.8%
10.0%SEK 325.00SEK 222.00SEK 329.4011
Oct ’24SEK 223.40
SEK 285.55
+27.8%
10.0%SEK 325.00SEK 222.00SEK 309.0011
Sep ’24SEK 211.00
SEK 284.18
+34.7%
10.1%SEK 325.00SEK 222.00SEK 320.0011
Aug ’24SEK 205.80
SEK 288.27
+40.1%
9.8%SEK 325.00SEK 222.00SEK 278.0011
Jul ’24SEK 210.40
SEK 286.80
+36.3%
10.4%SEK 325.00SEK 216.00SEK 285.8010
Jun ’24SEK 212.00
SEK 285.80
+34.8%
10.6%SEK 325.00SEK 216.00SEK 282.4010
May ’24SEK 249.40
SEK 287.20
+15.2%
11.5%SEK 325.00SEK 211.00SEK 285.4010
Apr ’24SEK 241.50
SEK 269.78
+11.7%
9.6%SEK 305.00SEK 211.00SEK 267.209
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
SEK 361.50
Fair Value
26.3% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/15 08:58
End of Day Share Price 2025/04/15 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Xue ChenBarclays
Rosie TurnerBarclays